BioSpace News Archive

Evolus, Inc. today announced that the Australian Therapeutic Goods Administration (TGA) has provided regulatory approval for Nuceiva ® (prabotulinumtoxinA)▼, a neurotoxin dedicated exclusively to aesthetics.

Viewpoint Molecular Targeting®, Inc., a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents, today announced the first dosing of two neuroendocrine tumor patients with therapeutic intent.

Akston Biosciences Corporation, a clinical-stage biotechnology company, today announced that John T. Preston, a founder of TEM Capital, has joined its Board of Directors.

Woebot Health today announced the enrollment of the first patient in a pivotal clinical trial to evaluate the safety and efficacy of WB001, an investigational digital therapeutic for postpartum depression (PPD) that was granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) in 2021.

Vector Atomic is developing high-performance optical atomic clocks and synchronization hardware for picosecond-level timing on a global scale.

LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, welcomes Michelle Futrell, MSN, MBA, RN, as Director of Lung Cancer Screening Programs and Initiatives.

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the “Company” or “PreveCeutical”), is pleased to announce that US patent no. 11,566,044, titled ‘Disulfide bond contai

Tevogen Bio today announced positive topline results from its Proof-of-Concept (POC) clinical trial designed to evaluate the safety and feasibility of TVGN 489, the company’s first clinical product of its precision T Cell therapy platform, for the treatment of acute high-risk COVID-19 patients.

Colorcon, Inc., a global leader in pharmaceutical film coatings and specialty excipients, announces that it has entered into a Put agreement to purchase Airnov Healthcare Packaging, portfolio company of Arsenal Capital Partners, a private equity firm.

Catalyst Pharmaceuticals, Inc. (“Catalyst”) (NASDAQ: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today commented on the FDA’s notice setting forth its position on Orphan Drug Exclusivity in light of the 11th Circuit’s decision in Catalyst Pharmaceuticals, Inc. v. Becerra.